Alexion Reports Fourth Quarter and Full Year 20... ( Soliris(R) Sales Reflect Strong 2007...)

HOME >> BIOLOGY >> TECHNOLOGY

Alexion Reports Fourth Quarter and Full Year 2007 Results

Date:2/14/2008

Soliris(R) Sales Reflect Strong 2007 Launch; Positioned for Expanded Growth in
U.S. and International Markets

Fourth Quarter and 2007 Financial Highlights:

* Soliris(R) (eculizumab) net product sales were $33.9 million in Q4 2007,

compared to net product sales of $21.8 million in Q3 2007.

* Q4 GAAP net loss was $12.3 million, or $0.33 per share, compared to a

GAAP net loss of $20.1 million, or $0.55 per share, in Q3 2007.

* Q4 non-GAAP net loss was $8.5 million, or $0.23 per share, compared to a

non-GAAP net loss of $14.0 million, or $0.38 per share, in Q3 2007.

* Total 2007 revenues were $72.0 million, including Soliris net product

sales of $66.4 million, representing the first nine months of Soliris

commercial availability.

* 2007 GAAP net loss was $92.3 million, or $2.54 per share, compared to a

net loss of $131.5 million, or $4.15 per share, in 2006.

* 2007 non-GAAP net loss was $72.1 million, or $1.99 per share, compared

to a net loss of $110.9 million, or $3.50 per share, in 2006.

CHESHIRE, Conn., Feb. 14 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter and year ended December 31, 2007.

Fourth Quarter 2007 Financial Results:

For the three months ended December 31, 2007, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported revenues of $33.9 million compared to revenues of $0.2 million for the same period in 2006. The revenues of $33.9 million for the fourth quarter of 2007 consisted entirely of Soliris(R) net product sales, compared to Soliris net product sales of $21.8 million in the third qu
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results

Post Your Comments:

Alexion Reports Fourth Quarter and Full Year 20...( Soliris(R) Sales Reflect Strong 2007...)